Karyopharm Therapeutics Inc.

Good morning. My name is Liz, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the CarioFarm Therapeutics First Quarter 2024 Financial Results Conference Call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Alhan Webb, Senior Vice President, Investor Relations.

Thank you, Lysol, and thank you all for joining us on today's conference call to discuss CARA Farm's first quarter 2024 financial results and recent company progress. We issued a press release this morning detailing our financial results for the first quarter 2024. This release, along with a slide presentation that we will reference during our call today, are available on our website. For today's call, as seen on slide two, I'm joined by Richard, Reshma, Sohani, and Mike, who will provide an update on our first quarter results and recent financing transactions that we announced this morning as well. Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements, or FNS, for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as outlined on slide three. Actual results may differ materially from those indicated by these FLS as a result of various important factors, including those discussed in the risk factors section of our most recent form 10-K, which is on file with the SEC, and in other filings that we may make with the SEC in the future. Any FLS represents our views as of today only. While we may elect to update this FLS at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on this FLS as representing our views as of any later date. I will now turn the call over to Richard. Please turn to slide four.

Good morning. Thank you, Elhan, and thank you all for joining today for CarioFarm's Q1 2024 earnings call. As you have seen, This morning, we have shared important news from a financial perspective that strengthens our potential to deliver on our innovation and growth strategy. I'll touch more on this in a moment. Turning to slide five, we have had a strong start to the year as we work to deliver our next stage of growth and advance our late-stage pipeline with trials that have the potential to enhance and create new standards of care for patients while providing significant value creation opportunities in the near term. Raishma will talk to our pipeline progress. Commercially, in the United States, we are pleased with our results this quarter in the highly competitive multi-myeloma market, including Exposio's growing role pre and post T cell therapies. Additionally, with our partners, we continue to expand Cellinexor's presence, including recent reimbursement decisions in both China and the United Kingdom. Sohani will talk to our commercial performance in the quarter. As we look to the future, the commercial infrastructure that we build provides us with the capability to support the rapid and smooth commercial launch of Cell and XOR in new indications if approved. We continue to believe that Cell and XOR can generate up to 2 billion of annual peak sales in the United States alone, depending on the outcome of our three pivotal phase three data readouts in 2025. As seen on slide six, Importantly, from a financial perspective, we have taken a significant step that improves our capital structure, strengthening our opportunity to realize the full value of our late-stage pipeline. Our comprehensive refinancing and amended royalty agreement announced this morning extends the vast majority of our debt maturities into 2028 and 2029, well beyond the expected data readouts and potential approvals of our three phase three programs. Finally, through continued disciplined execution and a concentrated pipeline, we have an expected runway into the end of 2025, providing us with the financial strength to deliver on our pivotal data readouts. Mike will discuss the details of the refinancing later on the call. Moving to slide seven, I would now like to turn the call over to Reshma to expand further on our pipeline and the progress we have made. Reshma?